Brought to you by 
Norgine gets European rights to Santarus' Zegerid
26 Oct 2009
Executive Summary
Santarus has licensed fellow specialty pharmaco Norgine exclusive rights to develop, manufacture, and commercialize immediate-release Zegerid incorporating omeprazole combined with one or more buffering agents in specified Western, Central, and Eastern European markets and in Israel.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Norgine gets European rights to Santarus' Zegerid
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice